NCT05666804 - Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Macular Polypoidal Choroidal Vasculopathy (PCV)

Interventions

DRUG

Brolucizumab 6mg

Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56

DRUG

Brolucizumab 6mg

Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56

Trial Locations (15)

13620

Novartis Investigative Site, Bundang Gu

35015

Novartis Investigative Site, Daejeon

42602

Novartis Investigative Site, Daegu

48108

Novartis Investigative Site, Busan

49241

Novartis Investigative Site, Busan

61469

Novartis Investigative Site, Gwangju